» Articles » PMID: 33757709

"I Felt Like I Had a Scarlet Letter": Recurring Experiences of Structural Stigma Surrounding Opioid Tapers Among Patients with Chronic, Non-cancer Pain

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2021 Mar 24
PMID 33757709
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Efforts to address opioid-involved overdose fatalities have led to widespread implementation of various initiatives to taper (i.e., reduce or discontinue) opioid prescriptions despite a limited understanding of patients' experience.

Methods: From 2019-2020, we recruited patients with chronic, non-cancer pain who had undergone a reduction in opioid daily dosage of ≥50 % in the past two years at Boston Medical Center or Michigan Medicine. Participants completed semi-structured interviews exploring health history, opioid use, and taper experiences. Inductive analysis, guided by theoretical conceptualizations of structural stigma, identified emergent themes.

Results: Among 41 participants, three elements of structural stigma were identified across participants' lives. First, participants identified themselves as overlooked subjects of the U.S. opioid crisis, who experienced overprescribing, subsequent stigmatization and surveillance of opioid use (e.g., toxicology screening, "pill counts"), and various tapering initiatives. Second, during the course of pain treatment, participants felt stigmatized and invalidated by cultural norms linking chronic pain to stereotypes of acting disingenuously (e.g., "drug-seeking"). Finally, during and after tapers, institutional policies and programs further increased participants' feelings of marginalization, producing multiple unintended consequences, including reduced access to medical care and feeling "orphaned by the system."

Conclusions: Opioid tapers may exacerbate the social production and burden of stigma among patients with chronic pain, especially when processes are perceived to invalidate pain, endorse stereotypes, and label previously effective, acceptable treatment as inappropriate. Findings highlight how various tapering initiatives reinforce the devalued status of people living with chronic pain while also reducing patients' wellbeing and confidence in medical systems.

Citing Articles

Community pharmacy's role in dispensing androgens and supporting harm reduction amid current policy dilemmas.

Piatkowski T, Ayurzana L, King M, Hattingh L, McMillan S Subst Abuse Treat Prev Policy. 2025; 20(1):2.

PMID: 39827172 PMC: 11748596. DOI: 10.1186/s13011-025-00636-y.


Strategies to Deimplement Opioid Prescribing in Primary Care: A Cluster Randomized Clinical Trial.

Quanbeck A, Robinson J, Jacobson N, Li X, Hennessy-Garza R, Landeck J JAMA Netw Open. 2024; 7(10):e2438325.

PMID: 39388183 PMC: 11581553. DOI: 10.1001/jamanetworkopen.2024.38325.


Accounting for the interplay of interpersonal and structural trauma in the treatment of chronic non-cancer pain, opioid use disorder, and mental health in urban safety-net primary care clinics.

Castellanos S, Cooke A, Koenders S, Joshi N, Miaskowski C, Kushel M SSM Ment Health. 2024; 4.

PMID: 38464953 PMC: 10923552. DOI: 10.1016/j.ssmmh.2023.100243.


Patient Experiences and Clinical Outcomes in a Multidisciplinary Perioperative Transitional Pain Service.

Manoharan D, Xie A, Hsu Y, Flynn H, Beiene Z, Giagtzis A J Pers Med. 2024; 14(1).

PMID: 38248732 PMC: 10821325. DOI: 10.3390/jpm14010031.


Predicting first use of heroin from prescription opioid use subtypes: Insights from the Monitoring the Future longitudinal panel.

Dash G, Gizer I, Slutske W Drug Alcohol Depend. 2024; 255:111084.

PMID: 38232646 PMC: 10842745. DOI: 10.1016/j.drugalcdep.2024.111084.


References
1.
Rieder T . Is Nonconsensual Tapering of High-Dose Opioid Therapy Justifiable?. AMA J Ethics. 2020; 22(1):E651-657. DOI: 10.1001/amajethics.2020.651. View

2.
Mark T, Parish W . Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat. 2019; 103:58-63. DOI: 10.1016/j.jsat.2019.05.001. View

3.
. Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011; 60(43):1487-92. View

4.
Frank J, Lovejoy T, Becker W, Morasco B, Koenig C, Hoffecker L . Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. Ann Intern Med. 2017; 167(3):181-191. DOI: 10.7326/M17-0598. View

5.
Waugh O, Byrne D, Nicholas M . Internalized stigma in people living with chronic pain. J Pain. 2014; 15(5):550.e1-10. DOI: 10.1016/j.jpain.2014.02.001. View